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One of the most significant effects of radiation therapy on normal tissues is mutagenesis,
which is the basis for radiation-induced malignancies. Radiation-induced malignancies are
late complications arising after radiotherapy, increasing in frequency among survivors of
both pediatric and adult cancers. Genetic backgrounds harboring germline mutations in
tumor suppressor genes are recognized risk factors. Some success has been found with
using genome wide association studies to identify germline polymorphisms associated
with susceptibility. The insights generated by genetics, epidemiology, and the develop-
ment of experimental models are defining potential strategies to offer to individuals at risk
for radiation-induced malignancies. Concurrent technological efforts are developing novel
radiotherapy delivery to reduce irradiation of normal tissues, and thereby, to mitigate the
risk of radiation-induced malignancies. The goal of this review is to discuss epidemiologic,
modeling, and radiotherapy delivery data, where these lines of research intersect and their
potential impact on patient care.
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INTRODUCTION
RADIATION-INDUCED TUMORS
Our understanding and application of radiation-based technolo-
gies has evolved to recognize both the therapeutic and potentially
detrimental effects of radiation exposure. That radiation could
interact with tissues to generate useful information (for example
radiographs),as well as acute injury,was recognized relatively early.
However, radiation exposure and radiotherapy specifically, also
produce delayed effects on normal tissues. One of the most dev-
astating consequences of radiation exposure is radiation-induced
tumorigenesis. Although the pathogenetic mechanisms underly-
ing radiation-induced tumorigenesis are not well-defined, study-
ing how normal tissues can be mutagenized by radiotherapy to
promote malignancies can yield important insights into cellular
and tissue responses to radiation-induced injury. This review will
discuss the settings in which radiation-induced tumors occur, the
known risk factors for radiation-induced tumorigenesis, models
developed to understand this process, and radiotherapy practice
in relation to this risk.
ATOMIC BOMB SURVIVORS
Individuals exposed to atomic bombs were of the general popula-
tion at Hiroshima and Nagasaki. Long-term follow up of atomic
bomb survivors has shown that tumor development was increased
in this population compared to non-irradiated individuals (Ron
et al., 1994; Thompson et al., 1994; Sadamori et al., 1996). Numer-
ous analyses of this important population have been reported
over the years and it is not our goal to summarize all of these,
as the exposure of this population differs substantially from the
delivery of radiotherapy. However, it is worth noting some of
the features of tumor development of this group, which predict
radiation-induced tumorigenesis in a clinical context.
Primary brain tumors in atomic bomb survivors included
meningiomas, schwannomas, and gliomas (Preston et al., 2002).
Notably, many tumors were diagnosed at autopsy, particu-
larly commonly low-grade tumors such as meningiomas and
pituitary adenomas, standing in contrast to radiation-induced
tumors identified in the clinical studies to follow. Dose-response
analyses revealed that linear dose-response for doses between
0 and 2 Sievert (Preston et al., 2002). Interestingly, plots of
tumor incidence against distance from detonation as a surro-
gate for radiation exposure dose showed that the incidence of
meningioma cases decreased significantly with increased dis-
tance (Sadamori et al., 1996). This radiation dose dependence
observed in some solid tumors is recapitulated in the radiotherapy
setting.
RADIATION-INDUCED TUMORS AFTER RADIOTHERAPY FOR
NON-ONCOLOGIC DISEASES
Early clinical applications for radiotherapy included a variety of
benign conditions, for example rheumatologic, dermatologic, and
infectious diseases. This is an important context in which late radi-
ation effects could be identified because, in contrast to malignant
diseases, the long survival of these patients accommodated the
long latency of radiation-induced tumorigenesis. This latency is a
hallmark of radiation-induced tumorigenesis, which was first for-
mally described by Cahan et al. (1948) in the 1940s. This classic
study describes a series of patients who received radiation ther-
apy for bone cysts, and after a latency of 5 or more years, then
developed in-field malignancies such as osteosarcomas.
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Low dose irradiation given over a few fractions has been used
in the past for diverse conditions such as tinea capitis (Modan
et al., 1974), acne (Albright and Allday, 1967), tonsillar hyperplasia,
hemangioma (Li et al., 1974), and ankylosing spondylitis (Smith
and Doll, 1982), resulting in the initiation of solid or hemato-
logic tumors. For example, low dose radiotherapy for ankylosing
spondylitis resulted in a significantly increased rate of death from
leukemias (Smith and Doll, 1982). Late radiation-induced malig-
nancies led to the abandonment of radiotherapy in the manage-
ment of these benign conditions. However, these early experiences
are worth reviewing because they provide substantial information
defining the relationship of radiation dose to tumor risk in the
general population, and such radiation dosing is unlikely to be
replicated in any modern clinical context.
The use of radiotherapy for tinea capitis led to the irradia-
tion of thousands of children receiving low dose, superficially
directed irradiation to the scalp, with lead shielding of the face
and neck typically employed (Ron et al., 1988a,b). These treat-
ments involved low energies of 100 kVp or less, intended to deposit
dose at superficial depths, and employed doses ranging from 1.0 to
6.0 Gy generally delivered in a single fraction, resulting in a mean
average dose to the brain of 1.5 Gy (Ron et al., 1988b). Long-term
follow up revealed that these treatments were associated with a
significant risk in the development of tumors in the head and
neck region and the central nervous system. The most frequently
occurring brain tumors were meningiomas followed by gliomas
(Ron et al., 1988b). Tumors were first noted 6 years after irradia-
tion and continued for at least 29 years, and there was no evidence
of a reduction of cancer risk toward baseline at the end of the
follow up period (Ron et al., 1988b). Additional analyses of this
cohort of patients estimated that statistically significant increases
in risk were observed for bone and connective tissue cancers and
leukemias (Ron et al., 1988a). Age at the time of irradiation also
appeared to influence risk of radiation associated neoplasms, with
children over the age of 10 at the time of irradiation at lowest risk,
and those irradiated between 5 and 9 years of age being at high-
est risk of developing leukemias and head and neck cancers (Ron
et al., 1988a).
These unique early data from low dose radiotherapy estab-
lish central features of radiation-induced tumorigenesis that are
further developed in the setting of modern radiotherapy. These
features are: (1) radiation-induced tumorigenesis occurs at low
dose levels and risk increases with dose, (2) the latency of tumor
detection is typically several years and can extend for decades,
and (3) young age at the time of exposure is a risk factor for
tumorigenesis.
SECOND MALIGNANT NEOPLASMS
Second malignant neoplasms (SMNs) are late complications aris-
ing after exposure to genotoxic therapies, which include radio-
therapy and some chemotherapeutic agents (Neglia et al., 1991).
SMNs comprise a significant fraction of subsequent malignan-
cies in cancer survivors (Table 1). SMNs account for most of the
∼90,000 s cancers diagnosed annually in the United States (Bhatia
and Sklar, 2002), and are a significant and growing late compli-
cation in survivors (Guibout et al., 2005; Henderson et al., 2007;
Armstrong et al., 2009a,b; Laverdiere et al., 2009; Meadows et al.,
2009; Breslow et al., 2010; Friedman et al., 2010; Ginsberg et al.,
2010; Castellino et al., 2011). Radiation-induced tumors comprise
the majority of SMNs. Similar to tumorigenesis after low dose
irradiation for benign diseases, SMNs also develop after a latency
of several years and sometimes decades (Kleinschmidt-DeMasters
and Lillehei, 1995).
Given the long latency of radiation-induced tumors, this is a
complication that preferentially affects cancer survivors, of which
there are an estimated 12 million in the United States (Under-
wood et al., 2012). Radiotherapy is an important component
of many cancer therapy paradigms, and diverse radiotherapy
approaches are used in variable settings. In addition, radiotherapy
is most commonly delivered focally, and therefore the spectrum
of radiation-induced tumors largely reflects the in-field tissues.
Survivors of pediatric cancers are at increased risk for developing
second and even third cancers, some of which are multiple and
distinct SMNs, and the reasons for this susceptibility are not well
understood (Armstrong et al., 2011). Defining and managing the
intrinsic, or background, cancer susceptibility of cancer patients
poses multiple challenges being addressed efforts in mathematical
modeling, experimental modeling, and radiation physics, as will
be discussed below. We will first outline major clinical settings in
which SMNs develop in order to highlight important themes in
radiation-induced tumorigenesis.
RADIOTHERAPY FOR LEUKEMIA
Total body irradiation (TBI) is a standard component of bone
marrow transplantation protocols, and leads to broad irradiation
of multiple anatomic regions and tissue types (Hill-Kayser et al.,
2011). Survivors of leukemias are at risk for developing diverse
malignancies, although SMNs related to cranial irradiation (CI)
represent a major fraction of SMNs (Neglia et al., 1991; Banerjee
et al., 2009; Rizzo et al., 2009).
Cranial or craniospinal irradiation is a major component of
leukemia therapy, typically used for high risk patients (Schmid
et al., 2005). Because long-term survival from childhood leukemia
has improved markedly over the last few decades (Neglia et al.,
1991), considerable data concerning late toxicities of cancer ther-
apy have been obtained from this group of patients. Data from
the Children’s Cancer Study Group examined 9720 children with
a diagnosis of acute lymphoblastic leukemia (ALL) most of whom
received chemotherapy, radiotherapy, or both. Some of these
patients received cranial or craniospinal irradiation at doses rang-
ing from 18 to 24 Gy (Neglia et al., 1991). With a median follow
up of 4.7 years, a retrospective cohort study estimated a sevenfold
excess for all cancers and a 22-fold excess of tumors of the central
nervous system (Neglia et al., 1991). Similar to the experience of
radiotherapy for benign diseases, the risk of central nervous system
tumors after irradiation was significantly higher in children 5 years
of age or younger at the time of diagnosis compared to patients
who were older than 5 (Neglia et al., 1991). Despite patients receiv-
ing chemotherapy, radiotherapy, and both, central nervous system
tumors developed in children who had been irradiated and no
association was observed with exposure to cyclophosphamide or
anthracyclines (Neglia et al., 1991). The most common SMNs in
these patients were tumors of the central nervous system, followed
by leukemias and lymphomas. The incidence of SMNs showed no
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evidence of reaching a plateau 15 years after diagnosis, suggesting
that the risk of SMNs after irradiation persists for an extended
period of time, and possibly is life-long. While modern efforts
are focused on implementing reduced-intensity conditioning reg-
imens, the feasibility of reduced-dose TBI is still unclear (Adkins
and DiPersio, 2008).
The Childhood Cancer Survivor Study (CCSS) is a multi-
institutional, long-term cohort study supported by the National
Cancer Institute and has performed numerous studies of late
effects of cancer therapy in survivors of childhood cancers. CCSS
published an important study describing a matched case-control
study of 14,361 5-year survivors of cancer (Neglia et al., 2006), the
largest series of cancer survivors to be assessed for SMNs. Brain
tumors were significant SMNs to arise in these childhood can-
cer survivors, with meningiomas being the most common CNS
primary tumor followed by glioma, most of these being high-
grade tumors (Neglia et al., 2006). The excess relative risk of brain
tumor increased with increasing dose for both these tumor types,
and similar to other studies, the excess relative risk was greatest
among children exposed at less than 5 years of age (Neglia et al.,
2006). In this large cohort of patients gliomas occurred at a median
of 9 years from the original cancer diagnosis and meningiomas a
median of 17 years, with no reduction in brain tumor incidence
with increased follow up. These data and data from other large
studies indicate that the risk of SMNs expressed as brain tumors
is sustained for decades and implies that survivors of childhood
cancers face continued risk of radiation-induced tumors as older
adults (Taylor et al., 2010).
Moreover, radiation-induced meningiomas are often multi-
ple, in contrast to meningiomas unassociated with prior radia-
tion therapy (Harrison et al., 1991). Their incidence is associ-
ated with younger age and tumors can be aggressive histologies
(Elbabaa et al., 2012). As compared to sporadic meningiomas,
these appear to possess distinct cytogenetics, including deletions
within chromosome 1p and 22q (Brassesco et al., 2012; Elbabaa
et al., 2012).
THORACIC IRRADIATION
Hodgkin disease (HD) is a malignancy involving lymph nodal
regions and is treated with chemotherapy and radiotherapy. HD
commonly involves cervical and mediastinal lymph nodes, and
classic radiotherapy for Hodgkin’s disease targets these nodal
regions, resulting in the irradiation of mammary tissues and lung.
The classic mantle field was designed decades ago to address the
nodal regions commonly involved in HD and consists of frac-
tionated radiation directed to the cervical, supraclavicular, infra-
clavicular, and mediastinal lymph nodes (Koh et al., 2007). This
broad nodal irradiation results in diverse normal tissues receiv-
ing radiation, with multiple late toxicities potentially developing.
Consequently, survivors of HD are at risk for developing radiation-
induced breast cancers (Dores et al., 2002; Aleman et al., 2003;
Basu et al., 2008; Crump and Hodgson, 2009; Milano et al., 2010;
Castellino et al., 2011), lung cancer (Gilbert et al., 2003), as well
as thyroid cancer (Hancock et al., 1991). Notably, the risk of
radiation-induced breast cancers in survivors of HD has been esti-
mated to be similar to that of individuals with BRCA1 mutations
(Travis et al., 2005a).
The risk of breast cancer after radiotherapy and chemotherapy
for HD is dose-dependent, with a dose of 4 Gy or more associ-
ated with a 3.2-fold increased risk compared to patients receiving
lower doses, and the risk increasing to eightfold with doses of more
than 40 Gy (Travis et al., 2003). The risk of breast cancer after
chemotherapy and radiotherapy appears to be primarily attrib-
utable to radiotherapy, as treatment with alkylating agents alone
resulted in a reduced risk. The risk of breast cancer decreased with
increasing number of alkylating agent cycles, likely reflecting the
reduced use of radiotherapy in these patients (Travis et al., 2003).
Similar to radiation-induced malignancies in other organs, the
risk of radiation-induced breast cancers persisted for more than
25 years (Travis et al., 2003). HD develops in adolescent girls and
young women, and in this group, low dose radiation to breast tis-
sue was associated with radiation-induced tumorigenesis. Overall,
this study estimated that among 1000 women treated for HD at
age 30 years or younger with mantle radiation alone using 40 Gy
and followed for 25 years, an excess of 83 breast cancers might be
observed, which might be reduced to a excess of 21 breast cancers
if radiation doses were lowered to 10 Gy (Travis et al., 2003).
Radiation-induced breast cancers can also develop after radio-
therapy of primary breast cancer, when tangential irradiation leads
to scatter of radiation to the contralateral breast (Hooning et al.,
2008). Women with breast cancer have up to 50% increased risk of
developing a secondary malignancy, which is largely attributable
to cancer development in the contralateral breast. Breast radiation
has been linked to high risk of lung cancer development (Rubino
et al., 2002), although modern radiotherapy techniques may fur-
ther minimize this risk (Inskip et al., 1994). The risk of breast
cancer is influenced by hormone status, as women with histories
of ovarian irradiation of 5 Gy or more had reduced risk of breast
cancer compared to women who did not (Travis et al., 2003). Con-
sistent with the hormone-dependence, radiation-induced breast
cancers were significantly less likely to develop in women who
were menopausal before the age of 40 (Travis et al., 2003).
HEAD AND NECK IRRADIATION
Radiotherapy is commonly used in the management of cancers
of the head and neck region. Historical rates of radiation-related
neoplasms has been estimated at 15% within 5 years of radio-
therapy in treatment of head and neck cancers, most of which
frequently arise in the head and neck, esophagus, or lung (Cooper
et al., 1989). The high incidence of SMNs following head and neck
radiotherapy may be augmented by dysplasia related to significant
tobacco and alcohol exposure, which are independent risk factors
for primary head and neck tumors, especially of the larynx and
hypopharynx (Lubin et al., 2009).
GENITOURINARY IRRADIATION
Although radiation-induced brain and breast cancers are common
SMNs in survivors of pediatric cancers, radiation-induced tumori-
genesis can occur after pelvic and abdominal irradiation. Survivors
of testicular cancer for example are at increased risk of develop-
ing radiation-induced tumors of the digestive and genitourinary
tracts (Travis et al., 1996, 2005b; van den Belt-Dusebout et al.,
2007). Similarly, survivors of cervical and endometrial cancers
who receive radiotherapy are at increased risk for second cancers
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arising in the colon, rectum, bladder, and genital sites (Chaturvedi
et al., 2007; Brown et al., 2010).
Survivors of prostate cancer are also at risk for developing
radiation-induced tumors (Zelefsky et al., 2012), which is partic-
ularly interesting given that these patients are generally treated at
substantially older ages than testicular or cervical cancer patients.
Recent SEER analysis for men with prostate cancer treated between
1988 and 2003 demonstrated a 1.88 relative risk of secondary blad-
der cancer incidence for those receiving external beam radiother-
apy as compared with prostatectomy (Nieder et al., 2008),although
this is influenced by tobacco exposure and may be decreasing in
the era of modern radiotherapy techniques (Boorjian et al., 2007).
HEMATOLOGIC MALIGNANCIES AS SMNs
Radiation-induced malignancies also include myeloid leukemias,
which develop in both humans and mice (Major and Mole, 1978;
Hijiya et al., 2009; Iwanaga et al., 2011). A case-control study in
a cohort of women with cervical cancer showed that the risk of
leukemia increased with increasing radiation doses of up to 4 Gy,
then decreased at higher doses (Boice et al., 1987). This data is
consistent with the leukemogenesis observed in other low dose
settings, such as treatments of benign disease (i.e., ankylosing
spondylitis) described above. Further, this dose dependence would
explain the predominance of solid tumors as SMNs after modern
radiotherapy, which employ much higher doses.
The development of hematologic malignancies after low dose
irradiation has been postulated to reflect the unique sensitivity of
bone marrow cells from which leukemias originate, with higher
radiation doses killing these cells so that mutagenesis cannot be
expressed as future disease.
MODIFIERS OF RADIATION-INDUCED TUMORIGENESIS
GENETIC BACKGROUND
Genetic backgrounds harboring germline mutations in tumor sup-
pressor genes are recognized risk factors for cancer in general and
also SMNs (Kleinerman, 2009). Tumor predisposition syndromes
highlight central molecules and pathways involved in cancer, for
example p53, and dysregulated Ras and Ras effector kinase signal-
ing [Cowden’s disease, tuberous sclerosis, and Neurofibromatosis
I (NF1)]. Germline mutations in Trp53 cause Li–Fraumeni syn-
drome, a cancer predisposition syndrome characterized by the
propensity to develop breast cancers, brain tumors, sarcomas, and
leukemias (Kemp et al., 1994; Hisada et al., 1998). Because the
background tumorigenesis risk in these individuals is so high,
estimates of the excess risk of cancer after radiation exposure
have been difficult to develop. However, given central role of
the p53 protein in DNA damage responses and cell cycle regula-
tion, it is highly likely that exposing individuals with Li–Fraumeni
syndrome to genotoxins will accelerate their risk of malignancy.
Individuals developing SMNs have been found to have germline
mutations in p53 (Malkin et al., 1992).
Familial retinoblastoma is probably the best characterized with
regard to excess risk of cancer development after radiation expo-
sure. Familial retinoblastoma is caused by a germline mutation
in the Rb gene, which produces the Rb protein involved in cell
cycle regulation (Sage, 2012). Familial retinoblastoma is typically
responsible for bilateral retinoblastoma in contrast to sporadic
retinoblastoma. A study by Wong et al. (1997) described the signif-
icantly elevated risk of second cancers in individuals with familial
as compared to sporadic retinoblastoma. The cumulative inci-
dence of second cancer at 50 years after diagnosis was 51% in
familial retinoblastoma compared to 5% for sporadic retinoblas-
toma (Wong et al., 1997). Irradiated patients commonly developed
soft tissue sarcomas, and interestingly the risk of developing a
radiation-induced sarcoma was apparent at a threshold dose of
5 Gy, and increased to 10.7-fold for doses exceeding 60 Gy (Wong
et al., 1997).
Germline mutations need not involve a known regulator of
DNA damage response; individuals with NF1 are at increased risk
of developing SMNs (Sharif et al., 2006) for unclear reasons. In
general, individuals with tumor predisposition syndromes should
be considered at risk for SMNs after radiation. Furthermore,
polymorphisms in metabolic pathways may influence SMN pre-
disposition by modulating repair of radiation-induced genotoxic
injury (Kelly and Perentesis, 2002).
INFLUENCE OF AGE
Survivors of pediatric malignancies are well documented to be at
risk for developing radiation-induced tumors (Neglia et al., 2006;
MacArthur et al., 2007). The reasons for this susceptibility are
not entirely clear, although it is postulated that genotoxic injury to
stem cells, which are generally more active in children as compared
to adults, may be a major mechanism for the observed difference
in susceptibility. Also contributing to this difference may be the
extended period of survivorship in survivors of childhood cancers.
However, there is growing awareness that survivors of adult
cancers also develop radiation-induced cancers after treatment of
a common malignancy such as prostate cancer (Zelefsky et al.,
2012). In contrast to SMNs in children, which are initiated by
genotoxin exposure, SMNs in middle-aged patients may be dri-
ven by promotion of pre-existing malignant cells (Shuryak et al.,
2010). This is an interesting distinction that may suggest different
strategies for SMN prevention in survivors of adult or childhood
cancers.
PATHOGENESIS OF RADIATION-INDUCED TUMORS
The molecular processes underlying susceptibility to and the
development of radiation-induced tumors are not well under-
stood. Tumorigenesis is underpinned by genetic alterations and
genomic injury is a known mechanism for radiation effects on
normal tissues. Currently, large scale, high genomic resolution
studies have not been performed on human radiation-induced
tumors to precisely characterize the genetic alterations that pro-
mote radiation-induced tumors. However, limited genetic analyses
have been performed for specific histologies, for example menin-
giomas (Rienstein et al., 2001; Al-Mefty et al., 2004). Copy number
analysis of radiation-induced and sporadic meningiomas suggests
that common tumorigenic pathways may be active in both types
of tumors (Rienstein et al., 2001).
Genome wide association studies (GWAS) have had some suc-
cess in identifying significant predictors of cancer susceptibility
in cancer survivors (Mertens et al., 2004; Best et al., 2011). How-
ever, experimental validation is also needed to justify and optimize
testing chemoprevention strategies for patients.
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MATHEMATICAL MODELS OF RADIATION-INDUCED TUMORIGENESIS
Radiation-induced tumors typically arise after long latencies, and
patient-based studies of SMN risk generally require follow up
information from thousands of patients to reliably detect and esti-
mate excess cancer risk after radiotherapy. There is a strong need
for models that permit accurate estimates of radiation-induced
cancer risk as oncologic care, and radiotherapy specifically, evolves.
Epidemiological data, particularly from atomic bomb survivors,
have been analyzed to develop models to help explain how the
excess relative risk of cancer is influenced by several factors and
how these relationships implicate specific mechanisms of tumori-
genesis. The biological process of tumorigenesis can be modeled
as radiation-induced initiation, or mutagenization of normal cells
that then become the seed for future malignancies. Different
assumptions influence these models with a central assumption
being that initiation decreases with increasing age at exposure,
due to the reduced time available for malignancy to develop. This
assumption may to explain the markedly higher risk of radiation-
induced SMNs in survivors of childhood cancers as compared
to survivors of adult cancers, and would predict that radiation-
induced cancer risk decreases as a function of increasing age at
exposure.
Analyses of cancer risks in atomic bomb survivors indicate that
the risk of radiation-induced cancers in middle-aged individuals
exposed exceeds that predicted by conventional initiation-based
model. Analyses by Shuryak et al. (2010) suggest that employ-
ing a combined model considering both initiation and promo-
tion may better estimate age-dependent risk, and that the risk
of radiation-induced tumorigenesis of middle-aged individuals,
which describes much of the adult cancer patient population, may
in fact be significantly higher than the risk estimated by initiation-
only based models. These models utilize organ-specific dose
volume histogram data commonly generated in modern radio-
therapy planning, and represent a uniquely radiotherapy-specific
phenomenon.
Additional modeling approaches consider how dose distribu-
tions within at risk organs influences radiation-induced cancer
risk (Schneider and Kaser-Hotz, 2005; Schneider et al., 2005).
Because increasingly conformal radiotherapy modalities differ
strikingly from the radiation dose distributions achieved with
two-dimensional treatment planning, at risk organs are exposed
to more variable dosing, and cancer risk estimation based on an
average organ dose does not account for intra-organ effects of
inhomogeneous dose deposition. The concept of organ equivalent
dose has been developed to account for intra-organ dose inhomo-
geneity, which has greater biological consequences at high doses
(Schneider et al., 2005).
Model-based estimates of radiation-induced tumorigenesis
allow predictions of future effects of currently evolving radiother-
apy technology, and more integrated analytical approaches may
uncover important insights (Shuryak et al., 2011).
MICROENVIRONMENTAL CONTRIBUTIONS TO RADIATION-INDUCED
TUMORIGENESIS
In addition to the directly mutagenizing effects of radiotherapy
on cells giving rise to tumors, changes in microenvironments after
irradiation are an important area of study and potential insight
into the complex process of tumorigenesis. Transplantation stud-
ies have demonstrated that irradiated microenvironments can
independently promote genomic injury in stem/progenitor cells
(Monje and Palmer, 2003) and enhance the expression of a neo-
plastic phenotype (Barcellos-Hoff, 1998; Nguyen et al., 2011).
Radiation exposure can influence the remodeling of the extracel-
lular matrix (ECM) as well as cell–cell and cell-ECM interactions
(Barcellos-Hoff, 2005).
THE BYSTANDER EFFECT
Most radiation-induced SMNs arise as tumors arising in the
irradiated region, or encompassed within the radiotherapy field
(“in-field” tumors), however there is evidence that the effects
of radiotherapy on non-targeted tissues can influence cell and
tissue function in diverse ways (Barcellos-Hoff, 2005; Shuryak
et al., 2007). The bystander effect, which has been observed
after radiation and chemical exposures, refers to a setting in
which untreated cells demonstrate abnormalities mimicking expo-
sure, such as chromosomal instability after irradiation (Moth-
ersill and Seymour, 2004). Radiation-induced signals transmit-
ted between irradiated (in-field) cells and neighboring unirra-
diated cells can promote the development of persistent reac-
tive oxygen species (ROS) in unirradiated cells (Widel et al.,
2012). This mechanism may promote tumorigenesis and bio-
physical models have been developed describing this process
(Shuryak et al., 2007). The precise mechanisms underlying the
bystander effect are not well-defined, but have been postulated
to involve secretable factors such as cytokines and intercellular
gap junctions (Mothersill and Seymour, 2004; Mancuso et al.,
2011).
CLINICALLY BASED ANIMAL MODELS OF SMNS
Clinical studies of SMNs are particularly challenging because: (1)
SMNs take years to develop, and patients can be lost to follow
up. This is particularly true of pediatric cancer survivors, who
transfer their care as adults. (2) Cancer survivors are genetically
diverse, have diverse primary tumor histologies and receive diverse
therapies, complicating studies to identify variables associated
with increased cancer susceptibility. Mouse models are potentially
powerful tools for dissecting mechanisms of human disease, but
murine studies of radiation mutagenesis have been limited in their
abilities to replicate clinical parameters. For example, murine stud-
ies of radiation-induced tumors have traditionally employed low
dose TBI (less than 3 Gy/fraction) (Ullrich et al., 1987, 1996; Mao
et al., 2005, 2008). This bears little resemblance to clinical prac-
tice, where most irradiated patients receive fractionated, focal,
high dose irradiation (40–70 Gy) to a site of disease, and adja-
cent normal tissues at risk for mutagenesis receive 50–100% of
the prescribed dose. Multiple studies indicate an important rela-
tionship between radiation dose and cancer risk in both cancer
survivors and atomic bomb survivors (Tucker et al., 1987; De Bruin
et al., 2009; Tukenova et al., 2011), with increasing doses associ-
ated with increasing risk of solid tumors. Data defining a clear
dose-response for soft tissue sarcoma development in irradiated
individuals with retinoblastoma (Wong et al., 1997) indicate that
the risk of radiation-induced tumorigenesis is clearly influenced
by both genetic background and the dosing of radiotherapy.
Frontiers in Oncology | Radiation Oncology April 2013 | Volume 3 | Article 73 | 6
Braunstein and Nakamura Radiotherapy-induced malignancies
Building on clinical observations of susceptibility to SMNs, we
developed mouse models of radiotherapy-induced tumorigenesis
using Nf1 mutant mice (Nakamura et al., 2011; Choi et al., 2012).
We first modeled SMN development after CI and found that in-
field solid tumor development after CI was significantly increased
in the Nf1 mutant background compared to wildtype, and that
the tumor histologies closely reflected SMN histologies arising
in cancer survivors (Nakamura et al., 2011). Focal radiotherapy
promoted the development of both hematologic and solid tumor
malignancies, and these classes of malignancies each developed
in a dose-dependent manner. Paralleling the dose relationship of
leukemia induction in irradiated patients, we found that hemato-
logic and solid malignancies segregated such that the incidence of
hematologic malignancies was reduced in high dose irradiation,
in contrast to solid tumors (Nakamura et al., 2011). Importantly,
radiation-induced tumors in our mouse models included well-
described human SMN histologies such as soft tissue sarcomas,
bone sarcoma, and carcinomas (Nakamura et al., 2011). These
robust models are now serving as useful experimental platforms
in which to study the interaction between genetic background and
radiation. One example of the utility of these models is illustrated
in the potential to perform comparative oncogenomic analysis.
Genomic damage induced by radiation exposure induces
genetic alterations, some of which will be selected for in the process
of tumorigenesis. Defining the common pathways responsible for
tumorigenesis after irradiation will yield important insights into
SMN pathogenesis and potentially reveal mechanisms that are
pharmacologically targetable. Comprehensive genomic analysis of
human SMNs has not been reported, most likely due to the scarcity
of high quality SMN tissue samples. To overcome this limita-
tion, comparative oncogenomics utilizes experimental mouse and
human cancer genetics to reach fundamental understanding of
important, conserved, and robust mechanisms of disease. Based on
the well-established susceptibility of the Nf1 mutant background
used in our models, we assessed NF1 status in radiation-induced
breast cancers from survivors of HD (none having NF1) and found
evidence of NF1 loss of heterozygosity (Choi et al., 2012), indicat-
ing that this loss occurs in human SMNs. Additional studies are
underway utilizing both human and murine radiation-induced
tumors to identify and validate genes playing a pathogenetic role in
SMN development. Identifying mechanisms important and com-
mon to SMN development may yield actionable targets for cancer
prevention. In cancer survivors suspected to be at high risk for
developing SMNs, it is currently not possible to predict with accu-
racy whether and in what tissues SMNs may develop. Efforts to
analyze human SMNs for shared mechanisms of tumorigenesis
have direct translational relevance because genetic changes could
represent new biomarkers or targets for cancer prevention/therapy.
RADIOTHERAPY TECHNIQUES
Fractionated external beam radiotherapy is most common and is
responsible for the majority of radiation-induced cancers. How-
ever, highly focal techniques have also been reported to produce
radiation-induced tumors, although at much reduced frequency
(Yu et al., 2000; Shamisa et al., 2001). For example, glioblastoma
multiforme, a malignant primary brain tumor that can develop
after fractionated radiotherapy, has been described as an SMN
after Gamma Knife radiosurgery (Yu et al., 2000), indicating that
SMNs can develop after high dose, high conformal, single fraction
irradiation.
FIELD SIZE
Radiation-induced malignancies are defined by regions of nor-
mal anatomy that are exposed to radiotherapy fields, a major
motivation for the use of conformal radiotherapy techniques and
reduction of field size is to limit normal tissue irradiation. This is
especially pertinent in children, where a greater relative fraction
of body tissue may be encompassed within standard radiation
fields (Das et al., 1997; Mazonakis et al., 2003). In the case of
radiation-induced tumors after HD radiotherapy, it has been esti-
mated that involved field radiotherapy, which would lower normal
tissue doses by excluding axillary irradiation, might reduce the 20-
year excess relative risks of breast and lung cancers by 63 and
21%, respectively (Hodgson et al., 2007). In fact, decreases in-field
size are associated with reduced incidence of SMNs after chest
irradiation (Sasse et al., 2012).
CONSIDERATION OF RADIOTHERAPY TREATMENT
MODALITY
Radiation-induced SMN may occur in tissues adjacent to the tar-
get tumor volume, situated within high dose radiation portal, and
generally characterized by sarcomatous histology (Dorr and Her-
rmann, 2002). Marked decrease in high dose treatment volumes
has been achieved by more conformal external beam treatment
technologies, brachytherapy approaches, and volume dose reduc-
tion protocols. Moreover, consistent patient immobilization and
image-guided delivery techniques have further constrained plan-
ning treatment volume expansions. However,SMNs may also arise,
and with much greater frequency, from low dose effects, typically
yielding carcinomas (Dorr and Herrmann, 2002). This low dose
complication is secondary to limitations in conventional beam
delivery techniques, resulting in non-therapeutic scatter dose to
tissues at distance from the primary treatment volume, which may
initiate carcinogenesis as a late treatment effect.
INTENSITY MODULATED RADIATION THERAPY
The development of modern external beam radiation delivery,
characterized by a technological transition from rectangular por-
tals, to irregular shapes with rigid collimation, to computer-
controlled multileaf collimators, has enabled increasingly precise
control of dose distribution to target tumor volumes (Brahme,
2001). This technology has developed in parallel with the emer-
gence of routine utilization of CT, MRI, and PET based 3D imaging
techniques as part of the treatment planning process (Photon
Treatment Planning Collaborative Working Group, 1991a,b; Gre-
goire et al., 2007). Thus, the cotemporaneous improved resolu-
tion of disease reinforced the clinical rationale of reduced treat-
ment volumes by means of incipient conformal radiation delivery
technologies.
Intensity modulated radiation therapy (IMRT), which employs
computer optimized control of photon fluence, has been ideal-
ized to augment the therapeutic window, by means of escalat-
ing the biologically effective dose yielding better tumor control
probability, with minimization of normal tissue complications
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(Intensity Modulated Radiation Therapy Collaborative Working
Group, 2001). Moreover, image-guidance has been integrated into
many IMRT systems, further increasing precision by addressing
inter- and intra-fraction variability in patient position and tar-
get motion during radiation treatment course (Mackie and Tome,
2008; Wu et al., 2011). A concern of IMRT has been the potential
large integral whole-body dose due to scatter radiation associated
with beam delivery, such that an extensive volume of susceptible
normal tissue may receive carcinogenic low dose radiation (Purdy,
2008). Despite a roughly twofold decrease in leakage with dynamic
multileaf collimators over static cerrobend blocks, as compared to
conventional delivery, IMRT requires longer beam-on time and
uses a larger number of treatment fields, thus delivering a larger
number of monitor units associated with greater integral whole-
body dose (Hall, 2006). Distant peripheral scatter doses may be
even greater for pediatric patients, attributed to their small stature
(Klein et al., 2006). Furthermore, while less widely reported, newer
Tomotherapy-based IMRT may be associated with an even greater
peripheral whole-body dose, possibly related to machine-specific
treatment energies and geometries (Wiezorek et al., 2009).
There are several mechanisms contributing to combined scat-
ter secondary radiation effects during IMRT delivery. Recognized
factors include electron beam energy, distance from target, tissue
depth, as well as multileaf collimator and gantry construction. At
energies of 10 MV and above, neutrons are generated via beam-
line interactions with the primary collimator, jaws, electron target,
and flattening filter. Whereas photons decrease exponentially with
distance from primary treatment volume, neutrons are a signif-
icant contributor to out-of-field dose with a deposition pattern
largely independent of distance to the target treatment field (Athar
et al., 2010). In clinical practice, IMRT energies upwards of 18 MV
are generally avoided due to the high relative biologic effective-
ness (RBE) of neutrons and the large monitor unit requirement
of IMRT (Kry et al., 2005a). There exists significant uncertainty
as to the RBE of low dose high-energy neutrons for the end-
point of carcinogenesis, but current tissue-based estimates derived
from A-bomb survivors and aberrant chromosome induction in
peripheral blood lymphocytes values confirm higher RBE as com-
pared to photons (Lloyd et al., 1976; Little, 1997; Preston et al.,
2003; Kellerer et al., 2006). Additional studies of neutron-induced
malignancies in animal models have demonstrated significant
variation in tissue specific RBE estimates (Brenner and Hall, 2008).
Intriguingly, while several groups suggest a small or negligible
contribution of scatter and secondary neutrons to SMN risk in a
variety of tissue types (Nath et al., 1984; Ruben et al., 2008), other
analyses have demonstrated increased risk up to eightfold due to
whole-body integral dose (Verellen and Vanhavere, 1999; Kry et al.,
2005b). Despite the issue of increased scatter, IMRT is estimated
to generate 285 excess fatal SMN per 105 per Gy, approximately
one-third less as compared to 425 for conventional photon ther-
apy, largely attributed to greater dose reduction to the non-target
volume by the primary beam (Lomax et al., 1999; Schneider et al.,
2002).
PROTON THERAPY
The use of charged particle beams for radiation delivery has fur-
ther refined dose distribution conformality of treatment volumes.
Proton therapy in particular, with its characteristic Bragg peak and
steep dose fall-off, has received great attention for the potential to
decrease radiation-induced SMN. Protons provide excellent tumor
volume dose distribution, with the added reduction of whole-
body integral dose during treatment delivery, by a factor of two to
three, as compared to IMRT and 3D conventional photon therapy,
respectively (Lomax et al., 1999; Miralbell et al., 2002). Moreover,
protons as compared to other charged particles, lack the additional
low dose tail beyond the Bragg peak that is characteristic of carbon
nuclei and may increase non-target dose (Jones, 2009). Carbon ion
therapy, however, with its higher linear energy transfer and RBE,
may offer an increased therapeutic ratio and support hypofrac-
tionation approaches (Brahme, 2004; Tsujii et al., 2004; Jones and
Burnet, 2005). Several ongoing phase I/II trials are exploring the
additional utility of carbon ion radiation with gliomas, hepato-
cellular, and rectal carcinoma as part of multimodal treatment
(Combs et al., 2010, 2011, 2012).
It has been estimated that excess fatal SMN may be thus further
reduced with proton therapy by two-thirds, to 158 per 105, as com-
pared to conventional photon therapy (Lomax et al., 1999; Cella
et al., 2001; Schneider et al., 2002). Much of this promise, how-
ever, is attributed to active-scanned therapy over more commonly
employed passive-scatter delivery techniques, which are associ-
ated with secondary neutron particle contamination. Notably,
the majority of currently employed clinical proton beams utilize
passive beam scattering in order to produce target-dose homo-
geneity. This technology introduces several components into the
beam path, including scattering material, flatteners, collimators,
and compensators, that result in production of high-energy sec-
ondary neutrons, as occurs with high-energy photon beam deliv-
ery (Fontenot et al., 2005). Of note, the dominant fraction of neu-
trons produced by proton delivery possesses energies over 100 MV,
which is distinct from IMRT-based secondary neutron production.
There exists limited data suggesting a geometrically higher RBE for
these very high-energy neutrons from passively scattered proton
delivery (Heimers, 1999; Mitaroff and Cern, 2002). This process
may therefore significantly increase the risk of SMN due to the
higher RBE neutrons as compared with other modalities (Agosteo
et al., 1998; Brenner and Hall, 2008), although there is some evi-
dence suggesting the risk may be no greater than that of scatter dose
from IMRT photon therapy (Shin et al., 2009). Active-scanned
therapy employs deflecting magnets to direct the proton beam
within the target tumor volume, without additional modulation,
obviating further interactions in the beamline path, with minimal
secondary neutron production on the order of 2 mSv per treatment
Gy (Schneider et al., 2002; Lomax et al., 2004). However, actively
scanned beam lines require a more technologically complex setup
that has hindered more widespread institution (Grozinger et al.,
2006). It may be noted that proton bombardment of target tis-
sues may produce internal secondary neutrons irrespective of
delivery method that appear to most significantly contribute to
secondary lung and hematologic malignancies (Schneider et al.,
2002; Brenner and Hall, 2008).
As previously discussed, the clinical significance is of whole-
body low-dose neutron exposure is unclear, but putatively has
a high potential for carcinogenesis [Brenner and Hall, 2008;
National Council on Radiation Protection and Measurements
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(NCRP), 1990]. Large volume exposures typical of craniospinal
dosimetric models suggest an attributable lifetime risk of SMN
up to 14.8% (fatal SMN risk of 5.3%), for passively scattered
proton therapy (Taddei et al., 2009, 2010). Thus, it is the neutron-
producing external scatter dose that is thought to be an“avoidable”
contributor to this substantial risk of SMN (Schneider et al., 2001).
CLINICAL COMPARISON OF MODALITIES
Risk of radiation-related cancers has been widely studied in
select patient groups. For cervical and prostate cancers, defin-
itive radiation-treated cohorts may be compared with surgical
controls. High dose treatment of cervical cancer was associated
with increased risk of multiple secondary malignancies including
bladder, rectal, vaginal, and non-Hodgkin’s lymphoma in women
(Boice et al., 1988; Chaturvedi et al., 2007). Increased risk of RT-
induced secondary malignancies in prostate cancer patients has
been noted in rectum, bladder, esophagus, and lung, particularly
for long-term survivors exceeding 10 years (Brenner et al., 2000;
Schneider et al., 2006). A recent pair of treatment planning studies
demonstrated a significantly diminished risk of SMN with pas-
sively scattered protons over 6-MV IMRT, for both early- and
advanced-stage prostate cancer radiotherapy, respectively. While
both techniques provided acceptable dose coverage to target vol-
umes, the proton plans demonstrated lower doses at low and
intermediate levels in the bladder and rectum (Chera et al., 2009;
Fontenot et al., 2009). A dosimetric analysis of prostate cancer
treatment from Schneider et al. (2007) further suggested the ben-
efits of proton therapy over IMRT and 3D conformal radiotherapy
(3DCRT) in dose-escalation models up to 100 Gy, with spot-
scanned proton delivery associated with a 40% decreased risk of
SMN as compared with 70 Gy 3DCRT.
Proton therapy has shown potential therapeutic benefit in treat-
ing adult malignancies in multiple other sites including the central
nervous system and gastrointestinal tract (Allen et al., 2012). It is
unclear if proton therapy offers superior outcomes in treatment
of lung cancer (Grutters et al., 2010). There is cautionary evi-
dence, however, for the necessity of appropriate image-guidance
and adaptive re-planning in proton delivery, as tumor response
over the treatment course may lead to greater dose deposition
within proximal normal tissues associated with increased risk of
acute toxicity and long-term SMN, which was not observed with
comparable IMRT plans (Chang et al., 2005; Hui et al., 2008; Koay
et al., 2012).
In older patients, the increased SMN risk with IMRT in long-
term survivors may be ultimately justified by improved tumor
control and reduced acute toxicity. However, this is less acceptable
in the pediatric population. As previously noted, the improve-
ment in cure rates for pediatric cancers has been associated with
increased lifetime risk for RT-induced SMNs in survivors having
received multimodal treatments that include radiation. Pediatric
patients are particularly sensitive to radiation effects due to their
developing organs, small stature, and potential long actuarial sur-
vival. This increased risk has been observed in studies of SMN
following radiation therapy in treatment of Hodgkin’s lymphoma
and testicular cancer in children and young adults (Wolden et al.,
1998; Travis et al., 2005b). Thus, for pediatric patients, proton
therapy has been viewed as especially potentially advantageous in
reduction of RT-induced SMNs as the superior dose distribution
allows for decreased integral, non-target, whole-body dose (Mer-
chant, 2009). There is no prospective data for SMN-incidence as
a primary endpoint for direct comparison of photon- vs. proton-
based radiation treatment. In addition to SEER and Children’s
Cancer Study Group reports, various groups have modeled SMN-
incidence based on guidelines of the International Commission on
Radiologic Protection or National Council on Radiation Protec-
tion and Measurements [National Research Council, 2006; Inter-
national Commission on Radiological Protection (ICRP), 1991],
accounting for primary target dose and secondary neutron scatter
dose deposition (Schneider et al., 2000, 2001; Jiang et al., 2005;
Schneider, 2005), noting the aforementioned concerns about the
accuracy of the applied estimates for neutron RBE in risk models,
as these are larger values extrapolated from A-bomb exposure data
(Hall, 2009).
Practical estimation of the incidence of radiation-induced
SMNs has been compared for IMRT vs. proton delivery plans
in treatment of a variety of pediatric tumor anatomic sites and
histologies. Miralbell et al. (2002) examined the advantage of
proton therapy, reporting a twofold or greater reduction in SMN-
incidence in a parameningeal rhabdomyosarcoma case and an 8-
to 15-fold reduction in a medulloblastoma case as compared with
IMRT or conventional X-ray delivery. Of note, however, this analy-
sis neglected the contribution of stray secondary neutrons to SMN
prediction,which was later addressed in a study by Newhauser et al.
(2009) that demonstrated maintained, although slightly dimin-
ished, benefit of lower SMN risk with both passively scattered and
scanned beam proton therapy. Another dosimetric study, by Lee
et al. (2005) compared proton, IMRT, and 3DCRT modalities for
several cases of pediatric retinoblastoma, medulloblastoma, and
pelvic sarcoma, with protons overall demonstrating both opti-
mal target dose coverage and normal tissue sparing, which may
ultimately reduce the risk of SMN.
CONCLUSION
Radiotherapy continues to be a critical component of oncologic
care. As cancer survival improves, the late effects of radiother-
apy can impact long-term patient health. The most significant
and life-threatening of late effects is the development of an SMN.
A review of the literature demonstrates that radiation-induced
tumors develop after relatively long latencies of often several years,
but that this risk often persists for decades without a plateau.
Defining the conditions that promote this complication will allow
us to develop both treatments and cancer preventive strategies for
individuals diagnosed with cancer (Figure 1). Low dose radiation
is associated with an increased risk of tumor development in a
variety of normal tissues, and susceptibility can be strongly influ-
enced by genetic background and likely additional factors. These
data should influence how we evaluate technologies and the care
of cancer survivors moving forward.
The majority of recent studies favor of proton therapy toward
a goal of reducing radiation-induced SMN, with spot-scanned
delivery being of greater advantage than passive-scatter at reducing
stray secondary neutrons, as compared with IMRT and 3DCRT. A
major limitation in these assessments is the lack of large scale ran-
domized controlled trials comparing late effects amongst different
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FIGURE 1 | Schematic of secondary malignant neoplasm (SMN) development.
modalities, with SMN as a specific endpoint. In addition, there
exists limited long-term secondary toxicity data for proton ther-
apy, as presented in several institutional case-series. Much of
the supporting evidence for protons is derived from theoretical
comparative dosimetric models, with SMN risk assessment by var-
ious measurement techniques or Monte Carlo calculations, using
generic or anthropomorphic phantom models, and with differ-
ent source data for risk modeling (Chaves et al., 2004; Rodrigues
et al., 2004; Fontenot et al., 2009; Taddei et al., 2009). The effects
of fractionation and dose-rate are also not generally considered
(Jones, 2009). Another significant concern in these comparative
models is the assumption of similar tissue specific dose-effect
curves independent of modality and the uncertainty of the true
RBE of high-energy neutrons (Miralbell et al., 2002; Newhauser
et al., 2009). While much of current SMN models are derived
from A-bomb survivor data, the pattern and histologies are dis-
tinct from those observed following radiotherapy (Pierce et al.,
1996; Hall, 2006). Moreover, the roles of chemotherapy, genetic-
predisposing, and environmental factors are not accounted for
in current models of radiation-induced SMN (Schneider et al.,
2001). More recent studies have confirmed gender and age at
exposure as highly significant factors in differential SMN risk
with proton therapy (Armstrong et al., 2007; Zacharatou Jarl-
skog and Paganetti, 2008; Taddei et al., 2010). Notably, these
limitations have been reflected in discrepancies between observed
and predicted SMNs (Goldstein et al., 1997; Miralbell et al.,
2002).
Ultimately, elevated risk of SMN remains an indelible late effect
of radiation therapy, regardless of radiation modality (Hall and
Wuu, 2003; Kry et al., 2005b; Brenner and Hall, 2008). Min-
imization of this risk is increasingly recognized as paramount,
as patients are experiencing improved outcomes, associated with
long-term survival, as a consequence of modern integrated treat-
ment approaches. As recognized by the NCRP, our understanding
of molecular biology and genetics must extend beyond the pri-
mary pathophysiology of presenting malignancy, in order to risk
stratify patients with regard to predisposition to radiation-induced
SMN, as part of individualized management (Travis et al., 2012).
Irrespective of the absolute SMN risk-reduction, current clini-
cal and theoretical evidence support proton therapy, especially
in treatment of pediatric malignancies (Allen et al., 2012). New
randomized trials will more conclusively evaluate the long-term
clinical benefit, and thus further justify the cost of widespread and
routine utilization of clinical proton technologies. In the interim,
recent pediatric protocols (e.g., medulloblastoma) are applying
risk-adaptive strategies that further diminish radiation extent
as part of multimodal cancer management (Gajjar et al., 2006;
Rutkowski et al., 2009; Ashley et al., 2012). Increasingly restricted
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planned treatment volumes are sought in dose-escalation for
lung and prostate cancer, afforded by image-guided techniques
that reduce target uncertainty (Song et al., 2005; Gomez and
Chang, 2011). Brachytherapy, as demonstrated in recent prostate
studies, may afford a decrease in non-target whole-body dose,
with slightly reduced rates of SMN (Liauw et al., 2006; Zelefsky
et al., 2012). Evolution of targeted therapies and radiosensitiz-
ers may further refine radiation exposure (Thomas et al., 2006;
Shewach and Lawrence, 2007). Expectantly, such refinements in
treatment approaches, concurrent with refinements in proton
and other particle beam delivery technologies that further reduce
“avoidable” secondary neutrons, will minimize the incidence of
treatment-related SMN.
Concurrent with the continued examination of and develop-
ment of technologies that minimize incidental irradiation normal
tissues, efforts to define the underlying biology are also criti-
cal because (1) there is already a large population of irradiated
cancer survivors for whom SMN risk is likely life-long and (2)
even highly conformal radiotherapy approaches will not entirely
eliminate SMN risk.
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